Menu Search
Equities

Aptechnaya Set' 36,6 PAO

APTK:MCX

Aptechnaya Set' 36,6 PAO

Actions
Consumer Staples Personal Care, Drug and Grocery Stores
  • Price (RUB)13.87
  • Today's Change-0.208 / -1.48%
  • Shares traded4.66m
  • 1 Year change+10.93%
  • Beta--
Data delayed at least 30 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aptechnaya Set' 36,6 PAO is a Russia-based company, involved in the retail of drugs and products for medical purposes, health and care goods, as well as distribution of medicaments. The Company holds the rights to the 36,6 brand and operates through the network of pharmacies across the Russian Federation. Its operational structure is divided into retail (Aptechnaya set' 36,6), pharmaceuticals production (Veropharm) and children goods (ELC). The Company operates through the chain of several pharmacies, numerous subsidiaries and affiliated companies located domestically, as well as on the territory of Cyprus.

  • Revenue in RUB (TTM)--
  • Net income in RUB--
  • Incorporated2002
  • Employees12.70k
  • Location
    Aptechnaya Set' 36,6 PAOul. Ivana Franko, d.8, 18 etazhMOSCOW 121108Russian FederationRUS
  • Phone+7 4 957925209
  • Fax+7 4 957978686
  • Websitehttps://pharmacychain366.ru/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		APTK:MCX since
announced		Transaction
value
Lekopttorg & Rodnik Zdorovia Pharmacy ChainDeal completed11 Sep 202311 Sep 2023Deal completed-16.21%--
Farmakon AODeal completed31 Aug 202331 Aug 2023Deal completed-19.51%--
Data delayed at least 30 minutes, as of May 02 2024.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Schroders IS Ltd.as of 30 Jun 20220.000.00%
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.